

**SYMPTOM CONTROL**

**GUIDELINES**

## PRINCIPLES OF MANAGEMENT

These guidelines have been developed for the use of health care professionals in the Hospital setting.

The principles are applicable to the care of patients dying from cancer and non malignant disease.

### **RECOGNISE THAT DEATH IS APPROACHING**

Studies have found that dying patients will manifest some or all of the following:

- Profound weakness - usually bedbound
- Drowsy or reduced cognition - semi-comatose
- Diminished intake of food and fluids - only able to take sips of fluid
- Difficulty in swallowing medications - no longer able to take tablets

### **TREATMENT OF SYMPTOMS**

The prime aim of all treatment at this stage is the control of symptoms current and potential.

Many medications which until now have been regarded as essential, can and should be discontinued, e.g.

anti-hypertensives  
replacement hormones  
vitamin supplements  
iron preparations  
hypoglycaemics  
long term antibiotics  
anti-arrhythmics  
diuretics  
steroids

**ONLY MEDICATIONS WHICH WILL CONTROL OR PREVENT DISTRESSING SYMPTOMS SHOULD BE USED AT THIS TIME**

The most common reported symptoms are:-

- Pain
- Nausea / Vomiting
- Agitation / Restlessness
- Excessive secretions / Noisy breathing

The algorithms attached will support you in your management of these symptoms.

## INTEGRATED CARE PATHWAY FOR THE DYING PATIENT

**All patients who are dying will have subcutaneous medication prescribed should any of these listed symptoms develop.**


**All medication needs must be reviewed after 24hrs. If two or more doses of prn medication have been required, then consider the use of a syringe driver (see Syringe Driver Guideline Booklet).**

**If a syringe driver is required, please obtain one via equipment library (ext. 2603)  
Not every patient who is dying will require a continuous subcutaneous infusion.**

**FOR ADVICE AND SUPPORT PLEASE CONTACT THE PALLIATIVE CARE TEAM  
(ext. 2290) OR PHARMACY (ext. 2266).**

INTEGRATED CARE PATHWAY FOR THE DYING PATIENT


**PAIN**



To convert from other strong opioids contact Palliative Care Team or Pharmacy ext 2266

if symptoms persist, contact the Palliative Care Team ext. 2290

**NAUSEA AND VOMITING**



**If symptoms persist contact the Palliative Care Team, ext. 2290**

INTEGRATED CARE PATHWAY FOR THE DYING PATIENT

**RESPIRATORY TRACT  
SECRETIONS**

**PRESENT**

1. **HYOSCINE HYDROBROMIDE 0.4mg s/c  
bolus injection stat. Commence a  
syringe driver 1.2mg over 24hrs**

2. **Continue to give prn dosage (0.4mg)  
accordingly**

3. **Increase total 24hrs dose to 2.4mg after  
24hrs if symptoms persist**


**ABSENT**

1. **HYOSCINE HYDROBROMIDE  
0.4mg s/c 4hrly prn**

2. **If two or more doses of prn HYOSCINE  
HYDROBROMIDE required, then  
consider a syringe driver s/c over 24hrs**

**If symptoms persist contact the  
Palliative Care Team ext. 2290**

**TERMINAL RESTLESSNESS  
AND AGITATION**



**If symptoms persist contact the  
Palliative Care Team ext. 2290**

**CHOICE OF DRUGS FOR USE IN SYRINGE DRIVERS  
(USUAL DOSE RANGES QUOTED)**

**DIAMORPHINE N.B.** Parenteral Diamorphine is 3 x stronger than oral morphine. If pain not controlled, increase dose by 30% to 50%

DRUG	USE	DOSE
CYCLIZINE (Antihistamine) 50 mg/ml injection	Broad spectrum antiemetic, centrally acting on vomiting centre Mix only with water	50 to 150 mg per 24hrs
HALOPERIDOL (Neuroleptic) 5 mg/ ml injection	Antiemetic - dose 2.5-10 mg over 24hrs Anxiolytic Control of hallucinations - 5-30 mg over 24hrs Caution in terminal restlessness with twitching - lowers seizure threshold	Usually 5mg per 24hrs
METOCLOPRAMIDE 10 mg in 2ml injection	Antiemetic (1) prokinetic (accelerates GI transit) (2) centrally acting on chemo-receptor trigger zone (CTZ), blocking transmission to vomiting centre (crystallisation may occur with Cyclizine, discard if injection discolours)	20 to 40mg per 24hrs
METHOTRIMEPRAZINE/ LEVOMEPRMAZINE (NOZINAN) (Phenothiazine) 25 mg/ml injection	Broad spectrum antiemetic, works on CTZ and vomiting centre (at lower doses) sedative (terminal agitation) ? analgesic effects	25 to 100mg per 24hrs
MIDAZOLAM (HYPNOVEL) (Benzodiazepine) 10 mg in 2ml	Sedative/anxiolytic (terminal agitation), anticonvulsant, muscle relaxant, controls myclonus	10 to 60mg per 24hrs
HYOSCINE HYDROBROMIDE (SCOPOLAMINE) (Antimuscarinic)	Antisecretory properties antiemetic, acts centrally on vomiting centre, anti spasmodic	0.4 to 1.8mg per 24hrs

**CAUTION Mixing drugs in Syringe Drivers (Drug Information - ext 2394 for further info)**

All of the above drugs are compatible with each other. It is advisable not to mix more than two drugs in one syringe. Please note certain other drugs may not be compatible and should not be mixed together in one syringe. Drugs not recommended for subcutaneous use are Diazepam, Chlorpromazine and Prochlorperazine because they cause skin irritation. Haloperidol may precipitate if concentration is > 2 mg 1ml in presence of Diamorphine. Cyclizine and Diamorphine may precipitate if Cyclizine concentration > 10 mg 1ml or if the concentration of either drug > 25 mg 1ml.

Haloperidol may precipitate if concentration is > 2 mg 1ml in presence of Diamorphine. Cyclizine and Diamorphine may precipitate if Cyclizine concentration > 10 mg 1ml or if the concentration of either drug > 25 mg 1ml.